Key result
Luteolin demonstrates preclinical cardioprotection by activating antioxidant pathways and suppressing inflammation.
Why the study?
To evaluate the cardioprotective effects of luteolin in mitigating critical pathological processes linked to cardiovascular diseases, including oxidative stress, inflammation, mitochondrial dysfunction, and endothelial damage.
Does luteolin provide cardioprotective effects in preclinical models of cardiovascular disease?
Does luteolin provide cardioprotective effects in preclinical models of cardiovascular disease?
Luteolin exhibits significant cardioprotective properties in preclinical models, highlighting its potential as a candidate for cardiovascular disease prevention and adjunctive therapy.
May support cardioprotection in CVD; hypothesis-generating and should not yet change practice.
To evaluate the cardioprotective effects of luteolin, a naturally occurring flavonoid, in mitigating critical pathological processes linked to cardiovascular diseases (CVDs), including oxidative stress, inflammation, mitochondrial dysfunction, and endothelial damage. Luteolin, found in celery, parsley, green peppers, and chamomile tea, exhibits significant cardioprotective properties through various mechanisms. It activates the Nrf2/HO-1 antioxidant pathway, suppresses NF-κB-mediated inflammation, regulates apoptosis, and preserves the functionality of endothelial nitric oxide synthase (eNOS). In preclinical studies involving isoproterenol- and doxorubicin-induced cardiotoxicity, luteolin was shown to reduce oxidative stress, decrease apoptosis, and improve cardiac structure and function. Compared to other flavonoids like quercetin and resveratrol, luteolin demonstrates more potent endothelial-protective effects and a balanced modulation of antioxidant and apoptotic pathways. The diverse actions and natural origin of luteolin make it a promising candidate for CVD prevention and as an adjunctive therapy. Future research should focus on rigorously designed clinical trials to validate its efficacy in heart failure, ischemic injury, and drug-induced cardiotoxicity, thus enhancing its application in clinical practice.
No takes yet. Share an insight, caveat, or question.
Javed et al. (2026) conducted a review in Cardiovascular diseases. Luteolin vs. Quercetin and resveratrol was evaluated on Cardioprotective effects (oxidative stress, inflammation, mitochondrial dysfunction, and endothelial damage). Luteolin exhibits significant cardioprotective properties in preclinical models by activating antioxidant pathways and suppressing inflammation, though clinical trials are needed to validate efficacy.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: